

*Short Communication*

# Explanation of COVID-19 Mortality Using Artificial Neural Network Based on Underlying and Laboratory Risk Factors in Ilam, Iran

Taghinezhad, F<sup>1</sup>, Kaffashian, M<sup>2</sup>, Kalvandi, Gh<sup>3</sup>, Shafiei, E<sup>4\*</sup>

1. Clinical Research Development Unit, Mostafa Khomeini Hospital, Ilam University of Medical Sciences, Ilam, Iran

2. Department of Physiology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran

3. Department of Pediatrics, School of Medicine, Besat Hospital, Hamadan University of Medical Sciences, Hamadan, Iran

4. Non-Communicable Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran

Received 7 August 2021; Accepted 10 October 2021

Corresponding Author: shafiei-e@medilam.ac.ir

---

## Abstract

The spread of new waves of coronavirus outbreaks, high mortality rates, and time-consuming and numerous challenges in achieving collective safety through vaccination and the need to prioritize the allocation of vaccines to the general population have led to the continued identification of risk factors associated with mortality in patients through innovative strategies and new statistical models. In this study, an artificial neural network (ANN) model was used to predict morbidity in patients with coronavirus disease 2019 (COVID-19). Data of 2,206 patients were extracted from the registry program of Shahid Mostafa Khomeini Hospital in Ilam, Iran, and were randomly analyzed in two training (1,544) and testing (662) groups. By fitting different models of a three-layer neural network, 12 variables could explain more than 77% of the mortality variance in COVID-19 patients. These findings could be used to better mortality management, vaccination prioritization, public education, and quarantine, and allocation of intensive care beds to reduce COVID-19 mortality. The results also confirmed the power of a better explanation of ANN models to predict the mortality of patients.

**Keywords:** Artificial neural networks, COVID-19, Multilayer perceptron, Iran

---

## 1. Introduction

Coronavirus disease 2019 (COVID-19), as the greatest crisis of the health system and the challenge of human society since World War II, has severely affected health systems, the global economy, and governments, causing widespread and unimaginable deaths (1). Moreover, unprecedented investments were made in the prevention, diagnosis, and treatment of the disease, reducing the incidence rate, and consequently, the mortality rate (2).

The greatest success against the recent pandemic can be attributed to the development of vaccines (3), a factor that raised great hopes for the eradication of the

disease. Currently, several different vaccination projects have been able to obtain emergency use licenses after passing the phases of being used for general vaccination (4). However, numerous challenges and obstacles, including the level and amount of production, reasonable prices for the purchase and maintenance particularly in low- and middle-income countries, proper and fair allocation, doubts, and incomplete acceptance of vaccination, have currently hampered the population safety and disease control (5, 6). On the other hand, the arrival of new waves of disease outbreaks and widespread mortality, along with the lack of adequate vaccines in countries, such as Iran,

have exacerbated the increasingly urgent situation. This has prioritized attempts to prevent the spread of the disease by reducing the incidence and mortality by identifying related risk factors (7, 8). On the other hand, the limited number of available vaccines, compared to the high number of applicants, has led to the identification of high-risk individuals in terms of risk of infection and mortality using low-cost contextual and laboratory variables to highlight vaccination as an important topic in the health policy-making (9).

At present, no definitive and golden method can predict the mortality rate of COVID-19 patients in terms of laboratory variables and underlying diseases. Creative and scientific study ideas for better management are challenges to control the incidence and mortality rates (2). One of the creative strategies is to use accurate statistical and mathematical methods (10) in explaining and predicting the importance of each risk factor and experimental changes in the incidence, prevalence, and mortality of patients (11). The prediction of the future situation based on existing variables will lead to better management and reduced costs in times of crisis (12). In the field of COVID-19 crisis management, understanding the relationship between different factors and variables and predicting events, such as mortality, are of interest to numerous researchers and health policy-makers and can pave the way for better decision-making in this area. Since the outbreak of the disease, clinical and laboratory factors, including changes in patients' lung computed tomography scan, changes in hematology tests (lymphopenia, thrombocytopenia, and leukocytosis), changes in some biochemical tests (changes in liver enzymes and increases in troponin, urea, and creatinine), changes in coagulation indicators (increase in prothrombin time and changes in D-dimer), and an increase in inflammatory indicators (increased erythrocyte sedimentation rate [ESR], C-reactive protein-10), have been extensively studied in various studies in addition to the COVID-19 diagnostic test by polymerase chain reaction (PCR; as the gold standard of diagnosis) (13, 14).

The artificial neural network (ANN) model is an example of such non-classical models that can be used

without any presuppositions, which is a kind of progress and transformation in various sciences, including medical sciences (15). The successful use of ANNs in numerous applications has been demonstrated in various articles in recent years. Practical examples include using this network in studies related to breast cancer and pancreatitis patients, explaining and predicting the number of hospitalization days in heart patients, explaining the possible effects of drugs on cancer patients, determining factors affecting hospital readmission, and explaining clinical results after prostate cancer chemotherapy (16, 17). Artificial neural networks are new information processing structures that use methods specific to biological neural networks. The main difference between the ANN and other common methods is that in this method, there is no need to consider a predetermined relationship between primary and secondary variables (18). Instead, these networks themselves discover the relationship between variables during the learning process. Artificial intelligence networks show their strength, especially in cases where there is a complex and nonlinear relationship between primary and secondary variables (19). As mentioned earlier in the use of classical models, they also require the existence of special assumptions, and the appropriateness of the model depends on the accuracy of these assumptions. Therefore, in cases where these assumptions do not seem correct using real data, it seems necessary to develop models that do not require such assumptions (20). Artificial neural network models have comparative advantages over other conventional methods. The need for theory and hypothesis, hypersensitivity to noise and error, the need for data completeness, difficult understandability path, and record relationships between multiple data are some of the limitations and problems with conventional and classical methods, which can be modified to a large extent in ANN models (21).

According to the results of studies, numerous factors can contribute to the poor prognosis and mortality of COVID-19 patients. On the other hand, most of the information about the epidemiological and laboratory

factors of COVID-19 is still incomplete and doubtful and there is insufficient evidence and certainty for its use. The recognition of the importance of each indicator related to death by the disease using efficient output models can be considered in the process of better treatment and care, management of scarce resources during the peak of the disease, prioritization of special and hospitalization beds, better human resource management in the health sector, increasing the reliability of patients with lower risk for home care, and appropriate planning to prioritize the allocation of vaccines to higher risk groups. Therefore, this study aimed to explain the role of underlying and laboratory risk factors in the mortality of COVID-19 patients using an ANN model.

## 2. Materials and Methods

### 2.1. Sample Collection

In the present retrospective cohort study, 21 field and laboratory variables were examined in 2,206 patients with confirmed PCR and definitive COVID-19 diagnosis who were referred to Mostafa Khomeini Hospital in Ilam, Iran, with a definitive diagnosis of COVID-19 from March 1, 2020, to March 20, 2021, and included in the study.

### 2.2. Input and Output Layers in Artificial Neural Network and Logistic Regression

The strength of ANNs and logistic regression models in explaining the mortality caused by COVID-19 was compared with the ability to explain logistic regression based on contextual and laboratory variables. Participants were randomly divided into two training and testing groups. Input variables, namely diabetes, body mass index (BMI), age, white blood cells, platelet, ESR, intubation, hypertension, chronic obstructive pulmonary disease (COPD), heart disease, hemoglobin, and cancer, were selected based on previous studies and preliminary analysis on the data of this study. The output variable was the patient's (deceased and non-deceased) condition. To

evaluate the predictive power, different ANN models were compared with the logistic regression. The variables were arranged in descending order in terms of their effects on the output variables in a stepwise logistic regression model. A box plot was used to identify these cases in nominal variables, and leverage methods were employed in numerical variables. The loss weighting method was utilized to obtain a robust and outlier-resistant regression model.

### 2.3. Artificial Neural Network Analysis

Two training and testing groups were used to produce ANNs. First, multilayer perceptrons with a hidden layer and a neuron in the outer layer were trained in the first group. Once the most effective possible combination was obtained to predict the output variable in the experimental group, it was used in this group. Network training was stopped when the prediction error in the training group was minimized using the mean square error. In the next step, the strength of ANN models and the logistic regression were compared with each other. The difference between the values predicted by the two models and the actual values of the output variable in each patient was compared using the mean squared difference method. This statistic follows the non-central Chi-square distribution. In addition, to obtain clinically tangible results, the diagnostic power of the models for separating deceased patients from normal individuals was determined by the receiver operating characteristic curve analysis. For this purpose, the differences of the area under the curve in different models were compared with each other. MATLAB version 9.3 and SPSS software version 26.0 were used to teach ANNs and analyze data, respectively.

## 3. Results


Among the participants, 2,206 patients were randomly divided into two training (n=1,544) and experimental (n=662) groups. The results of the two models in selecting important variables based on their impact factor are summarized in table 1.

**Table 1.** Status of selected variables in the regression model and artificial neural network model

The importance of variables in the ANN model	Importance of variables in the logistic regression model
Intubation	Intubation
Cancer	COPD
COPD	Heart disease
Heart disease	Age
Diabetes	BMI
BMI	Cancer
WBC	Diabetes
Age	ESR
ESR	Hemoglobin
Hemoglobin	HTN
PLT	WBC
HTN	PLT


ANN: Artificial neural network; BMI: Body mass index; PLT: Platelet; ESR: Erythrocyte sedimentation rate; COPD: Chronic obstructive pulmonary disease; HTN: Hypertension

After ANN analysis between risk factors, a significant difference remained between the 2 groups with regards to intubation (odds ratio [OR] 8.06, 95% confidence interval [CI]: 2.20-5.42,  $P=0.019$ ), cancer (OR 6.03, 95% CI: 1.97-2.45,  $P=0.046$ ), and COPD (OR 2.9, 95% CI: 4.14-7.12,  $P=0.022$ ), heart disease (OR 2.6, 95% CI: 3.60-4.18,  $P=0.016$ ) and diabetes (OR 2.36, 95% CI: 2.55-3.11,  $P=0.011$ ) (Figure 1).



**Figure 1.** Odds ratio values calculated by artificial neural network

According to figure 2, the accuracy rate for the best neural network model and logistic regression were 89.76 and 78.66, respectively. The values obtained for this index show the superiority of the ANN model over the logistic regression model.



**Figure 2.** Results of receiver operating characteristic model comparing logistic regression and neural network models

#### 4. Discussion

This study predicted the variables that had an important role in the mortality of COVID-19 patients. In this regard, 12 variables were selected using ANN models. It is of interest to numerous health researchers and policy-makers to understand the relationship between different factors and variables and predict events, such as mortality, which can pave the way for better decision-making in this area.

Based on the results of the present study, having intubation, cancer, COPD, heart disease, and diabetes greatly influenced mortality incidence as male patients were shown to be more vulnerable, which was inconsistent with the findings of the studies (22-25). Furthermore, the results of our study confirmed that aging (>55 years old) was associated with death in COVID-19 patients. Previous evidence demonstrated that COVID-19 infection was more likely to affect older males with comorbidities and could result in fatal respiratory diseases, such as acute respiratory disease syndrome (26). In addition, it was revealed that other risk factors might be associated with aging, such as diabetes, respiratory system disease, and cardiovascular

disease, which was consistent with the findings of other studies (27, 28). Previously, evidence confirmed that hypertension and diabetes were more prevalent in patients with severe Middle East respiratory syndrome infection. Correspondingly, the mortality rate of influenza was significantly higher in patients with hypertension, metabolic disease, cardiovascular diseases, and respiratory system disease (29-31).

Intubation, older age (>50 years old), BMI, hypertension, heart disease, diabetes, COPD, and cancer were associated with a greater risk of death from COVID-19 infection (32). The results of the present ANN analysis could help clinicians to identify high-risk groups that should receive off-label medications or invasive supportive care as soon as possible. Given that almost all existing suppliers' forecasting models use linear and logistical methods for analysis, the use of nonlinear relationships detected in ANN systems can design more effective screening programs for people who have died from COVID-19. The use of these models, especially in population screening programs estimating small amounts, can cause drastic changes in reducing mistakes to show their superiority. This improvement makes screening programs more targeted to find people with a high risk of death, resulting in enhanced coverage, cost, and effectiveness of these programs.

#### Authors' Contribution

F. T. developed and designed the evaluation, collected the clinical data, and drafted the manuscript. F. T. and Sh. E. participated in the study conception and design, supervised the study, and revised the manuscript critically for important intellectual contents. Sh. E. revised the manuscript critically for important intellectual contents. All authors read and approved the final manuscript.

#### Ethics

This article is approved by the Medical Ethics Committee of the Ilam University of Medical Science,

Ilam, Iran (No. IR.MEDILAM.REC.1399.247). The principles of research ethics, honesty, and transparency were considered in all stages of the study.

#### Conflict of Interest

The authors declare that they have no conflict of interest.

#### Grant Support

This research project was financially supported by Ilam University of Medical Sciences, Ilam, Iran.

#### Acknowledgment

We would like to thank our co-workers in the clinical research department unit of Shahid Mostafa Khomeini Hospital, Ilam, Iran.

#### References

1. D'Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management. *Clin Gastroenterol Hepatol*. 2020.
2. Brown RJ, Head MG. Monitoring investments in coronavirus research and development. *Lancet Microbe*. 2020;1(2):e61.
3. Calina D, Sarkar C, Arsene AL, Salehi B, Docea AO, Mondal M, et al. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. *Immunol Res*. 2020:1-10.
4. Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. *Cell Death Differ*. 2021;28(2):626-39.
5. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. *Lancet*. 2021;397(10278):1023-34.
6. Mullard A. How COVID vaccines are being divvied up around the world. *Nature*. 2020.
7. Mirzaee S, Jalalinejad R, George B. Country of Origin, Covid-19 Vaccine and the Future of Travel: a Preliminary Study in Iran. *Anais Brasileiros de Estudos Turísticos-ABET*. 2021.
8. Nourmohammadi H, Azami G, Taghinezhad F,

- Shafiei E. Risk and benefit of antiplatelet therapy in Covid-19 patients with cancer and thrombocytopenia: letter to the editor. *Cancer Invest.* 2021;39(3):217-8.
9. Mills MC, Salisbury D. The challenges of distributing COVID-19 vaccinations. *EClinicalMedicine.* 2021;31.
  10. Nademi A, Shafiei E, Valizadeh R, Sciences B. Forecasting Psychological Symptoms in Mild Traumatic Brain Injury: A Nonparametric Approach. *Iran J Psychiatry Behav Sci.* 2019;13(3).
  11. Shafiei E, Fakharian E, Omidi A, Akbari H, Delpisheh A, Nademi A, et al. Comparison of artificial neural network and logistic regression models for prediction of psychological symptom six months after mild traumatic brain injury. *Iran J Psychiatry Behav Sci.* 2017;11(3).
  12. Niazkar HR, Niazkar M. Application of artificial neural networks to predict the COVID-19 outbreak. *Glob Health Res Policy.* 2020;5(1):50.
  13. Li Y, Xia L. Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management. *Am J Roentgenol.* 2020;214(6):1280-6.
  14. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. *Lancet Haematol.* 2020;7(6):e438-e40.
  15. Abdulaal A, Patel A, Charani E, Denny S, Mughal N, Moore L. Prognostic modeling of COVID-19 using artificial intelligence in the United Kingdom: model development and validation. *J Med Internet Res.* 2020;22(8):e20259.
  16. Fei Y, Hu J, Gao K, Tu J, Li W-q, Wang W. Predicting risk for portal vein thrombosis in acute pancreatitis patients: A comparison of radical basis function artificial neural network and logistic regression models. *J Crit Care.* 2017;39:115-23.
  17. Liu Q, Shan M, Zhu H, Cao J, Chen R. Noninvasive ventilation with a helmet in patients with acute respiratory failure caused by chest trauma: a randomized controlled trial. *Sci Rep.* 2020;10(1):21489.
  18. Zhang Z, Beck MW, Winkler DA, Huang B, Sibanda W, Goyal H. Opening the black box of neural networks: methods for interpreting neural network models in clinical applications. *Ann Transl Med.* 2018;6(11).
  19. Paul PK, Chatterjee D, Ghosh M. Neural Networks: Emphasizing its Application in the World of Health and Medical Sciences. *J Adv Med.* 2012;1(2):93-9.
  20. Moftakhar L, Mozghan S, Safe MS. Exponentially increasing trend of infected patients with COVID-19 in Iran: a comparison of neural network and ARIMA forecasting models. *Iran J Public Health.* 2020.
  21. Zheng M, Wu C, Yang K, Yang Y, Liu Y, Gao S, et al. Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis. *Pharmacol Res.* 2020:105367.
  22. Sepandi M, Taghdir M, Alimohamadi Y, Afrashteh S, Hosamirudsari H. Factors associated with mortality in COVID-19 patients: a systematic review and meta-analysis. *Iran J Public Health* 2020;49(7):1211.
  23. Zhang X-B, Hu L, Ming Q, Wei X-J, Zhang Z-Y, Chen L-D, et al. Risk factors for mortality of coronavirus disease-2019 (COVID-19) patients in two centers of Hubei province, China: A retrospective analysis. *PloS One* 2021;16(1):0246030.
  24. Albitar O, Ballouze R, Ooi JP, Ghadzi SMS, practice c. Risk factors for mortality among COVID-19 patients. *Diabetes Res Clin Pract.* 2020;166:108293.
  25. Jordan RE, Adab P, Cheng K. Covid-19: risk factors for severe disease and death. *Br Med J.* 2020.
  26. Leung C. Clinical features of deaths in the novel coronavirus epidemic in China. *Rev Med Virol.* 2020;30(3):e2103.
  27. Canning D, Karra M, Dayalu R, Guo M, Bloom DE. The association between age, COVID-19 symptoms, and social distancing behavior in the United States. *MedRxiv.* 2020.
  28. Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. *J Clin Virol.* 2020;127:104354.
  29. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. *Int J Infect Dis.* 2016;49:129-33.
  30. Patel SK, Velkoska E, Freeman M, Wai B, Lancefield TF, Burrell LM. From gene to protein—experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. *Front Physiol.* 2014;5:227.
  31. Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in? *Clin Exp Pharmacol Physiol.* 2013;40(8):551-9.
  32. Ryan JJ, Melendres-Groves L, Zamanian RT, Oudiz RJ, Chakinala M, Rosenzweig EB, et al. Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic. *Pulm Circ.* 2020;10(2).